Your browser is no longer supported. Please, upgrade your browser.
Settings
RDHL [NASD]
RedHill Biopharma Ltd.
Index- P/E- EPS (ttm)-2.30 Insider Own- Shs Outstand46.68M Perf Week2.04%
Market Cap229.79M Forward P/E- EPS next Y-0.39 Insider Trans- Shs Float34.99M Perf Month-30.50%
Income-95.00M PEG- EPS next Q-0.21 Inst Own18.40% Short Float5.28% Perf Quarter-28.41%
Sales84.50M P/S2.72 EPS this Y-46.80% Inst Trans-28.72% Short Ratio2.33 Perf Half Y-31.64%
Book/sh0.63 P/B7.92 EPS next Y50.00% ROA-49.10% Target Price- Perf Year-50.00%
Cash/sh1.20 P/C4.16 EPS next 5Y- ROE-303.30% 52W Range4.48 - 11.52 Perf YTD-38.24%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-63.20% 52W High-56.68% Beta1.58
Dividend %- Quick Ratio1.10 Sales past 5Y635.00% Gross Margin50.50% 52W Low11.38% ATR0.61
Employees182 Current Ratio1.20 Sales Q/Q2.90% Oper. Margin-91.40% RSI (14)34.11 Volatility6.73% 8.91%
OptionableYes Debt/Eq2.97 EPS Q/Q-39.00% Profit Margin- Rel Volume0.76 Prev Close4.94
ShortableYes LT Debt/Eq2.91 EarningsAug 26 BMO Payout- Avg Volume794.19K Price4.99
Recom1.70 SMA20-31.12% SMA50-28.81% SMA200-33.74% Volume606,875 Change1.01%
Aug-31-21Initiated Cantor Fitzgerald Overweight $22
May-18-21Initiated H.C. Wainwright Buy $23
Sep-11-20Initiated BTIG Research Buy
Jul-12-19Upgrade WBB Securities Buy → Strong Buy
Mar-12-19Upgrade WBB Securities Speculative Buy → Buy
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Sep-29-15Initiated Nomura Buy
Jul-29-15Reiterated ROTH Capital Buy $30 → $31
Jun-17-15Reiterated H.C. Wainwright Buy $23 → $32
Jun-15-15Reiterated ROTH Capital Buy $27.50 → $30
Sep-23-21 07:00AM  
Sep-15-21 11:40AM  
Sep-14-21 12:02PM  
08:15AM  
Sep-13-21 09:10AM  
07:02AM  
07:00AM  
Sep-08-21 10:29AM  
Sep-07-21 07:56AM  
07:02AM  
06:02AM  
06:00AM  
Sep-02-21 10:35AM  
10:00AM  
Sep-01-21 10:44AM  
Aug-31-21 04:11PM  
Aug-26-21 08:44AM  
07:56AM  
07:50AM  
07:30AM  
07:00AM  
06:30AM  
06:00AM  
06:00AM  
Aug-23-21 07:05AM  
07:00AM  
Aug-19-21 07:00AM  
Jul-22-21 09:45AM  
09:19AM  
Jul-20-21 08:00AM  
07:00AM  
Jul-19-21 10:15AM  
07:21AM  
07:00AM  
07:00AM  
Jul-13-21 11:00AM  
Jun-28-21 07:00AM  
Jun-21-21 07:30AM  
07:00AM  
07:00AM  
Jun-18-21 02:53PM  
Jun-15-21 03:04PM  
Jun-09-21 07:00AM  
Jun-07-21 07:00AM  
May-27-21 07:15PM  
07:05AM  
07:00AM  
06:45AM  
May-26-21 11:06AM  
07:12AM  
07:00AM  
May-25-21 08:00AM  
May-24-21 07:00AM  
May-21-21 12:15PM  
May-20-21 07:00AM  
Apr-11-21 06:15AM  
Apr-09-21 07:00AM  
Mar-25-21 09:15AM  
Mar-22-21 07:00AM  
Mar-18-21 08:18AM  
Mar-11-21 07:00AM  
Mar-05-21 07:00AM  
Mar-04-21 12:10PM  
Mar-02-21 09:06AM  
08:23AM  
Mar-01-21 04:53PM  
Feb-23-21 08:07AM  
07:33AM  
07:13AM  
07:03AM  
Feb-18-21 01:00PM  
07:00AM  
Feb-17-21 07:00AM  
Feb-11-21 06:55AM  
Feb-09-21 07:00AM  
Jan-29-21 07:45AM  
07:26AM  
07:00AM  
Jan-28-21 09:03AM  
08:02AM  
07:27AM  
Jan-26-21 06:20AM  
Jan-14-21 02:13PM  
Jan-12-21 12:56PM  
08:51AM  
Jan-11-21 04:35PM  
07:00AM  
07:00AM  
Jan-08-21 02:11PM  
Jan-07-21 09:28AM  
Jan-06-21 07:00AM  
Jan-04-21 09:41AM  
Dec-31-20 09:38AM  
09:30AM  
Dec-28-20 11:28AM  
Dec-22-20 07:00AM  
Dec-15-20 11:42AM  
09:30AM  
Dec-14-20 08:00AM  
Dec-07-20 07:00AM  
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.